Related Experiment Video
Updated: Mar 13, 2026
08:22
Isolation and Flow Cytometric Assessment of Neuroimmune Interactions in a Mini-Stroke Murine Model
Published on: June 20, 2025
557
Partial MHC class II constructs as novel immunomodulatory therapy for stroke.
Gil Benedek1, Arthur A Vandenbark2, Nabil J Alkayed3
1Neuroimmunology Research, VA Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd, Portland, OR, 97239, USA; Department of Neurology, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA.
Neurochemistry International
|November 5, 2016
Summary
Novel partial MHC class II constructs show promise for treating ischemic stroke by reducing brain damage and improving recovery. These therapies target inflammation, offering a new avenue for stroke prevention and treatment.
Area of Science:
- Neuroscience
- Immunology
- Cardiovascular Medicine
Background:
- Global stroke prevalence is increasing, necessitating new therapeutic strategies beyond current acute treatments like tPA and mechanical thrombectomy.
- Inflammation significantly contributes to brain injury following cerebral ischemia, highlighting the need for therapies targeting pro-inflammatory pathways.
- Partial MHC class II constructs have demonstrated efficacy in managing various inflammatory conditions by modulating immune cell activity.
Purpose of the Study:
- To review the potential of partial MHC class II constructs as a novel therapeutic approach for ischemic stroke.
- To evaluate the efficacy of these constructs in preclinical models of cerebral ischemia.
Main Methods:
- Review of existing literature on partial MHC class II constructs and their application in inflammatory diseases.
- Analysis of studies using partial MHC class II constructs in rodent models of cerebral ischemia, assessing infarct volume and neurological deficits.
- Examination of effects on splenic atrophy and CNS immune cell phenotypes (M2 macrophages/microglia).
Main Results:
- Partial MHC class II constructs effectively reduced infarct volume and neurological deficits in mouse models of cerebral ischemia.
- These constructs reversed stroke-associated splenic atrophy.
- Treatment promoted a shift towards a protective M2 macrophage/microglia phenotype in the central nervous system, aiding tissue repair.
Conclusions:
- Partial MHC class II constructs represent a promising novel treatment strategy for ischemic stroke, addressing inflammation and promoting recovery.
- Further research, including validation in large animal models, is needed to meet STAIR criteria for clinical trials.
